Artículos

Phase Ii randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

CONTENIDO DE LIBRE ACCESO

Este contenido es de libre acceso. Solo haz clic en el siguiente botón.

Autor
Año de publicación 2013
Idioma Inglés
Publicado por Radiation Oncology; Vol. 8

Descripción: Background and purpose: Chloroquine (CLQ), an antimalarial drug, has a lysosomotropic effect associated with increased radiationsensibility, which is mediated by the leakage of hydrolytic enzymes, increased apoptosis, autophagy and increased oxidative stress in vitro. In this phase II study, we evaluated the efficacy and safety of radiosensibilization using CLQ concomitant with 30 Gray (Gy) of whole-brain irradiation (WBI) to treat patients with brain metastases (BM) from solid tumors. Methods: Seventy-three eligible patients were randomized. Thirty-nine patients received WBI (30 Gy in 10 fractions over 2 weeks) concomitant with 150 mg of CLQ for 4 weeks (the CLQ arm). Thirty-four patients received the same schedule of WBI concomitant with a placebo for 4 weeks (the control arm). All the patients were evaluated for quality of life (QoL) using the EORTC Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) (Mexican version) beforebeginning radiotherapy and one month later. Results: The overall response rate (ORR) was 54% for the CLQ arm and 55% for the control arm (p=0.92). The progression-free survival of brain metastases (BMPFS) rates at one year were 83.9% (95% CI 69.4-98.4) for the CLQ arm and 55.1% (95% CI 33.6-77.6) for the control arm. Treatment with CLQ was independently associated with increased BMPFS (RR 0.31,95% CI [0.1-0.9], p=0.046).The only factor that was independently associated with increased overall survival (OS) was the presence of< 4 brain metastases (RR 1.9, 95% CI [1.12-3.3], p=0.017). WBI was associated with improvements in cognitive and emotional function but also with worsened nausea in both patients groups. No differences in QoL or toxicity were found between the study arms. Conclusion: Treatment with CLQ plus WBI improved the control of BM (compared with the control arm) with no increase in toxicity; however, CLQ did not improve the RR or OS. A phase III clinical trial is warranted to confirm these findings.
Citación recomendada (normas APA)
: Luis Leonardo; Arce Salinas Rojas Puentes, "Phase Ii randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases", -:Radiation Oncology; Vol. 8, 2013. Consultado en línea en la Biblioteca Digital de Bogotá (https://www.bibliotecadigitaldebogota.gov.co/resources/2087703/), el día 2025-05-19.

Información adicional

Temas
- Otros
- Medicina
Derechos de uso Derechos reservados
Fuente Biblioteca Virtual Banco de la República
Términos y condiciones de uso Más información aquí
Año de publicación 2013
Formato PDF

Phase Ii randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Información adicional

Contenidos relacionados

Fundamentos de neurociencia

Calidad y auditoría en salud

¡Disfruta más de la BDB!

Phase Ii randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Información adicional

Mis colecciones

¿Eliminar esta reseña?